Frank Dahlke

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

Ludwig Kappos, Amit Bar‐Or, Bruce Cree et al. · The Lancet · 2018 · 925 citations

Medicine, Neurology, Pharmacology +9

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

Jens Kühle, Harald Kropshofer, Dieter Haering et al. · Neurology · 2019 · 564 citations · Full text

Life Sciences, Neurology, Neuroscience +17

How patients with multiple sclerosis acquire disability

Fred Lublin, Dieter A. Häring, Habib Ganjgahi et al. · Brain · 2022 · 528 citations · Full text

Education, Neurology, Disability Management +13

The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis

P. D. Molyneux, Ludwig Kappos, Chris H. Polman et al. · Brain · 2000 · 241 citations · Full text

Medicine, Neurology, Neuroscience +14

Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study

Krzysztof Selmaj, David K.B. Li, Hans-Peter Hartung et al. · The Lancet Neurology · 2013 · 233 citations

Pharmacy, Neurology, Pharmacotherapy +7